Latest News for: oral presentation

Edit

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Nasdaq Globe Newswire 19 Feb 2026
APLS) today announced that eight abstracts were ...
Edit

MHNCS 2026 Oral Presentation: Ficerafusp alfa (2000mg Q2W) and pembrolizumab in HPV-negative first-line recurrent/metastatic head and neck squamous cell carcinoma (Bicara Therapeutics Inc)

Public Technologies 19 Feb 2026
) Ficerafusp alfa (2000 mg Q2W) and pembrolizumab in HPV-negative first-line recurrent/metastatic head and neck squamous cell carcinoma. Dan P. Zandberg, John M. Kaczmar, Assuntina G. Sacco, Glenn J ... Wong. Presenter ... Presenter ... Presenter ... Presenter ... Presenter.
Edit

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem ...

The Galveston Daily News 09 Feb 2026
EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 9, 2026-- ....
Edit

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the ...

Rutland Herald 03 Feb 2026
EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 3, 2026-- ....
Edit

Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem

Nasdaq Globe Newswire 29 Jan 2026
... oral presentation at the upcoming Tandem Meetings 2026 on February 7 in Salt Lake City, USA.
Edit

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual ...

Nasdaq Globe Newswire 23 Jan 2026
Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer ...
Edit

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of

Caledonian Record 23 Jan 2026
WATERTOWN, Mass., Jan.
Edit

Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American

Hastings Tribune 20 Jan 2026
NEW HAVEN, Conn., Jan.
Edit

Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society ...

Nasdaq Globe Newswire 20 Jan 2026
(“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel ...
Edit

2026 MASH-TAG Oral Presentation: HepQuant DuO® Reveals Functional and Physiological Heterogeneity to Support Enhanced Clinical ...

HJ News 12 Jan 2026
HepQuant, a leader in developing noninvasive, blood-based, ...
Edit

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 (Actuate Therapeutics Inc)

Public Technologies 12 Jan 2026
... pancreatic cancer were featured in oral and poster presentations at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9, 2026 ... Oral Presentation.
Edit

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

The Facts 24 Dec 2025
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX.
Edit

HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

Rio Grande Sun 12 Dec 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors ... .
Edit

Siolta Therapeutics Announces Upcoming Late Breaking Oral Presentation of Results from the Phase 2 ADORED ...

Polk County Itemiser-Observer 11 Dec 2025
SAN CARLOS, Calif., Dec.
Edit

ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting

Black Hills Pioneer 10 Dec 2025
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting ....

Article Search

tools
×
×
×
×